Global Stem Cells Market 2020 (COVID-19) Impact Analysis: Business Trends, Growth Insight, Statistics And Forecast to 2025 – Surfacing Magazine

Global Stem Cells Market Growth (Status and Outlook) 2020-2025 published by MarketandResearch.biz presents immense clarity on the market size, share, and growth rate across different regions. The report is a comprehensive representation of the global Stem Cells market area through research, development, and analysis of information collected from different sources.

Read more
Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma – Cancer Network

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeting CAR T-cell therapy, yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline findings from the pivotal phase 2 KarMMA trial shared during the 2020 ASCO Virtual Scientific Program. In the study, 33% of patients had a complete response with ide-cel. The median duration of response (DOR) was 10.7 months, and the median progression-free survival (PFS) was 8.8 months (95% CI, 5.6-11.6)

Read more
Study reveals birth defects caused by flame retardant – University of Georgia

Research focuses on mans exposure prior to conception A new study from the University of Georgia has shown that exposure to a now-banned flame retardant can alter the genetic code in sperm, leading to major health defects in children of exposed parents. Published recently in Scientific Reports, the study is the first to investigate how polybrominated biphenyl-153 (PBB153), the primary chemical component of the flame retardant FireMaster, impacts paternal reproduction.

Read more
Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO) – PRNewswire

SUZHOU, China and SHANGHAI, May 29, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, today announced that two presentations were accepted at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Both presentations can be found in the Development Therapeutics Immunotherapy session, central on Gracell's TruUCAR GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) patients and EnhancedCAR GC008t in patients with advanced mesothelin-positive solid tumors.

Read more